GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gilead Sciences Inc (GILD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive analyst sentiment, and promising growth catalysts in the biotech sector. While the stock lacks immediate trading signals, its fundamentals and future outlook make it a solid long-term investment.
The technical indicators suggest a neutral to slightly bullish trend. The MACD is positive and contracting, indicating potential momentum. The RSI is neutral at 41.468, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support is at 137.692, and resistance is at 142.238.
Strong financial performance in Q4 2025, with revenue up 4.70% YoY and net income up 22.43% YoY.
Positive analyst ratings and raised price targets, with multiple firms maintaining Buy or Overweight ratings.
Recent partnership to expand access to HIV prevention drugs, showcasing growth potential and social impact.
Jim Cramer and analysts recommend holding the stock for future gains.
Regular market price decline of -0.87%, though this is offset by post-market recovery (+0.28%).
Broader competitive pressures in the pharmaceutical industry due to U.S. drug pricing policies and rising competition from China's biotech sector.
In Q4 2025, Gilead reported a 4.70% YoY revenue increase to $7.93 billion, a 22.43% YoY increase in net income to $2.18 billion, and a 25.18% YoY EPS growth to $1.74. Gross margin also improved slightly to 79.51%. These figures indicate strong growth and profitability.
Analysts are overwhelmingly positive, with multiple firms raising price targets (e.g., Citi to $165, Morgan Stanley to $175, Truist to $155). The consensus reflects confidence in Gilead's growth prospects, particularly in HIV treatments and other biopharma innovations.
